DiNAQOR is a pioneering company in the field of gene therapy, focusing on the development of innovative and targeted genetic therapies, particularly for cardiomyopathies and heart failure. The company has established a proprietary platform that emphasizes human-based tissue drug development, enabling organ-specific delivery of gene therapies. This approach addresses significant unmet medical needs in the treatment of cardiovascular diseases, which are among the leading causes of mortality.

Central to DiNAQOR's technology is its proprietary Engineered Heart Tissue (EHT) technology, which utilizes human-induced pluripotent stem cell cardiomyocytes. This technology serves as a test bed for gene therapy, facilitating rapid translation of research findings into clinical applications. Additionally, the company employs a proprietary Loco-Regional Perfusion (LRP) system that allows for the direct delivery of gene therapies to heart tissue and other solid organs. This targeted delivery method minimizes systemic exposure and off-target effects, while also enabling the possibility of repeat dosing, thereby enhancing the efficacy and safety of gene therapy treatments.

Switzerland

DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and  Hamburg, Germany.

Cardiovascular Diseases

Genetic Diseases

Kidney Diseases

Urogenital Diseases

DiNAQOR

Hypertrophic cardiomyopathies

DINA-003

Gene Therapy

Arrhythmogenic right ventricular cardiomyopathy

DINA-002

Dilated Cardiomyopathy

DINA-004/005

DINA-006

Autosomal Dominant Polycystic Kidney Disease

DINAK-001

DINAK-002

Glomerular diseases

DINAK-003

DINAK-004

Europe - West

Adeno-associated viral vector (AAV)

Antiviral Therapies

Biologics

Cell Therapies

Stem Cells

Therapeutic

DiNAQOR

Company Details